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Insulin-producing cells (IPCs) derived from human pluripotent stem cells (hPSCs) may be useful in cell
therapy and drug discovery for diabetes. Here, we examined various growth factors and small molecules
including those previously reported to develop a robust differentiationmethod for induction ofmature IPCs
from hPSCs. We established a protocol that induced PDX1-positive pancreatic progenitor cells at high
efficiency, and further induced mature IPCs by treatment with forskolin, dexamethasone, Alk5 inhibitor II
and nicotinamide in 3D culture. The cells that differentiated into INSULIN-positive and
C-PEPTIDE-positive cells secreted insulin in response to glucose stimulation, indicating a functional IPC
phenotype. We also found that this method was applicable to different types of hPSCs.
A
t present, islet transplantation is considered to be one of the most effective therapies for the treatment of
patients with severe diabetes1–3. However, the shortage of donor human pancreases limits such clinical
therapy. Human pluripotent stem cells (hPSCs), including human embryonic stem cells (hESCs) and
induced pluripotent stem cells (iPSCs)4,5, have replication competence and the ability to differentiate into many
cell types. Furthermore, they are reported to be a potential source of b cells for cell therapy6,7. hPSCs may also be
used as tools in drug discovery research, such as development of new drugs using diseasemodel cells derived from
disease-specific iPSCs8–11. For the realization of such therapies it is crucial to efficiently generate insulin-pro-
ducing cells (IPCs) from PSCs.
Several protocols have been reported to induce IPCs from hPSCs11–22, which mimic the differentiation process
during pancreatic development. These methods are effective in IPCs induction. Pancreatic development is
regulated by transcriptional factors, including PDX1, NGN3, NEUROD1, PAX4, NKX2.2 and NKX6.1, and
controlled by various morphogens23,24. The pancreas is derived from definitive endoderm (DE) that develops
frompluripotent cells in the early embryo. DE differentiates into gut endoderm containing pancreatic progenitors
expressing PDX1 (PDX11), a transcription factor that plays important roles in organogenesis of the pancreas
including the endocrine and exocrine tissues. PDX11 pancreatic progenitors give rise to INSULINpositive (INS1)
cells, and other transcription factors such asNGN3,NEUROD1, PAX4,NKX2.2 andNKX6.1 are expressed during
this process. Subsequently, INS1 cells undergo ‘‘maturation’’ to fully functional islet b cells that secrete insulin in
response to glucose. These mature IPCs are thought to be characterized by their expression of maturationmarker
genes such as MAFA.
Although previous reports have succeeded to differentiate mature IPCs from DE cells, the efficiency of
differentiation into PDX11 cells is generally low and not consistent among hPSC lines. These problems have
hampered the generation of sufficient numbers of mature IPCs for the treatment of patients with severe diabetes.
It has been suggested that the differentiation conditions have not been optimized for induction of PDX11 and
INS1 cells. Because the generation of PDX11 and INS1 cells is one of the most critical steps for mature IPC
differentiation, we considered it to be necessary to establish an efficient differentiation method to induce PDX11
and INS1 cells for production of mature IPCs. In addition to the difficulty to produce INS1 cells, previously
generated INS1 cells have been reported to exhibit inferior functions compared with those of mature IPCs22.
Therefore, it is also indispensable to devise a method to induce mature IPCs.
In this study, we focused on development of a differentiation method to induce PDX11 and INS1 cells by
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reported to promote differentiation of hPSCs into INS1 cells. We
applied a three step protocol to induce mature IPCs from hPSCs. DE
cells were induced from hPSCs in Stage I, PDX11 cells were induced
from DE cells in Stage II, and INS1 cells and mature IPCs were
induced from PDX11 cells in Stage III.We found that optimal induc-
tion of each differentiation step enables efficient differentiation of
hPSCs intomature IPCs. FOXA21/SOX171 cells were approximately
91% of total cells, and PDX11 cells were approximately 76%. INS1
cells were approximately 10% of total cells using a combination of
small molecules, but these INS1 cells did not secrete insulin in res-
ponse to glucose stimulation. Using 3D culture, INS1 cells derived
from different hPSC lines were approximately 30% of the total cells
and secreted insulin in response to glucose stimulation and our
method can be applied to various hPSC lines.
Results
High efficiency differentiation of hESCs into DE. First, we examined
the efficiency of DE cell induction from hPSCs. Activin A has been
used to induce DE cells in most reports. More recently, it has been
shown that the combination of activin A with Wnt3a results in more
efficient induction of DE cells11,14,16,18,21,25,26. In addition to these
factors, we chose six growth factors and small molecules from
other relevant reports, and examined the differentiation efficiency
of DE cells by changing the combinations and concentrations of
these factors (Table S1). Screening for maximal induction
conditions was performed by analyzing the expression of DE
marker genes, CXCR4, FOXA2 and SOX17, and primitive gut tube
marker genes, HNF1B and HNF4A, by quantitative PCR. The
percentage of FOXA2 and SOX17 double-positive (FOXA21/
SOX171) cells was evaluated by flow cytometry. KhES-3 cells, a
hESC line, were treated with activin A for 4 days and then
examined for their expression of FOXA2, SOX17, CXCR4, HNF1B
and HNF4A. The expression of these genes increased by treatment
with activin A (Figs. 1A and S1A). Differentiation efficiency was
evaluated by flow cytometric analysis of FOXA21/SOX171 cells,
revealing that the percentage of FOXA21/SOX171 cells was 37.3 6
8.5% (Fig. 1B). We treated the cells with activin A for 4 days because
any longer caused cell death. Next, we evaluated combinations of
activin A and other factors, which resulted in higher levels of
marker gene expression than those achieved by activin A treatment
alone. Treatment with both activin A and Wnt3a resulted in higher
expression levels of marker genes compared with that by activin A
treatment alone, and the percentage of FOXA21/SOX171 cells
increased to 59.7 6 8.6% (Fig. S1B). We next elucidated the
pathway of Wnt3a in differentiation of DE cells. CHIR99021, a
glycogen synthase kinase 3b (GSK3-b) inhibitor, is a specific
activator of the canonical Wnt pathway. Therefore, we examined
the effect of CHIR99021 instead of Wnt3a. After treatment with
activin A and CHIR99021, the percentage of FOXA21/SOX171
cells was 60.5 6 2.0%, which was similar to that achieved by
treatment with activin A and Wnt3a (Figs. 1B and S1B). The
results showed that Wnt acted via the canonical pathway rather
than the non-canonical Wnt pathway in the induction of DE cells.
For higher efficiency of differentiation into DE cells, we screened
combinations of other factors. Treatment with the combination of
activinA, CHIR99021 andwortmannin, a phosphoinositide 3-kinase
(PI3K) inhibitor, for 2 days and then activin A and CHIR99021 for a
further 2 days increased the expression of FOXA2, SOX17, HNF1B
and HNF4A (Figs. 1A and S1A). The percentage of FOXA21/
SOX171 cells was 91.6 6 0.3% of total cells (Fig. 1B). Wortmannin
treatment for 4 days resulted in extensive cell death. Expression of
FOXA2 and SOX17 proteins was examined by immunocytochemis-
try, revealing colocalization of these proteins (Fig. 1C). Treatment
with other factors did not affect the expression of FOXA2, SOX17,
HNF1B or HNF4A as shown by quantitative PCR analysis (data not
shown). These results showed that the combination of activin A,
CHIR99021 and wortmannin synergistically induced DE cells from
hPSCs.
Differentiation of DE cells into pancreatic progenitor cells. Because
we established a highly efficient differentiation method that induced
up to 90% of the total cell population into DE cells, we next tried to
improve the differentiation efficiency of PDX11 (pancreatic
progenitor) cells from DE cells. It has been reported that treatment
with Noggin, an inhibitor of bone morphogenetic protein (BMP)
signalling, retinoic acid and fibroblast growth factor (FGF)7 or
FGF10 induces PDX11 cells from DE cells16,22,25,27,28. To evaluate
these factors in differentiation of PDX11 cells (Table S1), the
expression of pancreatic progenitor markers PDX1 and HNF6 were
analysed by quantitative PCR and the percentage of PDX11 cells was
examined by an immunochemical assay using an anti-PDX1
antibody. Treatment with Noggin or dorsomorphin, an inhibitor of
BMP type I receptors ALK2, 3 and 6, increased the expression of
HNF6 and PDX1 to similar levels (Fig. 2A), and the percentage
of PDX11 cells was also comparable (33.7 6 10.3% and 33.7 6
11.1%, respectively) (Fig. 2B). These results showed that both BMP
signalling inhibitors acted with similar efficiencies, and the
combination of these factors increased PDX11 cells to 39.2 6 6.2%
(Fig. 2B). Next, we used retinoic acid for differentiation of PDX11
cells, and found that the percentage of PDX11 cells was 18.4 6
6.5% (Fig. 2B). Because it was reported that activation of the ERK
pathway antagonizes the effects of retinoic acid29, we examined the
combination of FR180204, an inhibitor of ERK1/2, and retinoic acid.
As a result, the percentage of PDX11 cells was increased to 58.2 6
6.2% (Fig. 2B). Next, we evaluated the combination of Noggin,
dorsomorphin, retinoic acid and FR180204, which increased the
expression of HNF6 and PDX1 (Fig. 2A), and PDX11 cells were
67.3 6 4.8% of total cells in the immunochemical assay (Fig. 2B).
Moreover, we found that the combination of FGF10, retinoic acid,
Noggin, dorsomorphin and FR180204 increased the expression of
HNF6, PDX1 and endocrine progenitor markers, including NKX6.1,
NKX2.2 and NGN3 (Figs. 2A and S2A).In addition, the percentage of
PDX11 cells was increased to 76.5 6 6.7% (Fig. 2B). FGF10 treatment
was performed for 3 days because the expression of PDX1 and the
percentage of PDX11 cells were not different at 3 and 6 days (Fig.
S2B). The expression of PDX1 was not significantly increased by
treatment with other factors (data not shown). These results
suggested that the combination of these five factors acted
synergistically to efficiently induce PDX11 cells from DE cells.
Next, we applied our differentiation method developed using
KhES-3 cells to other hPSC lines, including H9, iPS (IMR90)-4
and iPS 253G1. All four cell lines showed differentiation into
PDX11 cells at an efficiency of 70–80%, suggesting our method is
applicable to a wide variety of PSC lines (Fig. 2C).
Induction of pancreatic progenitor cells into INS1 cells. PDX11
cells could be differentiated at a high efficiency of more than 70%.
Next, we developed a differentiation method to induce INS1 cells.
It has been reported that the factors used to induce PDX11 cells have
no effect on the expression of INS22. Therefore, we hypothesized
that other signals participated in the differentiation of PDX11 cells
into INS1 cells19,30. To generate INS1 cells, we screened growth
factors and small molecules that have been reported to regulate
differentiation11,14–16,18–22 (Table S1). Although single treatments
with dexamethasone, glucocorticoid, nicotinamide, or Alk5 inhibi-
tor II did not increase the expression of INS or GLUCAGON (GCG),
treatment with forskolin alone or forskolin, Alk5 inhibitor II and
nicotinamide increased the expression of those genes (Fig. 3A).
Moreover, the combination of forskolin, dexamethasone, Alk5
inhibitor II and nicotinamide obviously increased the expression of
INS, GCG and pancreatic endocrine marker genes, including NGN3,
NKX2.2,PAX4 andNEUROD1, but had no effect on the expression of
NKX6.1 and the maturation maker gene,MAFA. (Figs. 3A and S3A).
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This result suggested that dexamethasone was necessary for differen-
tiation of INS1 cells. Expression of INS was not significantly
increased by treatment with other factors (data not shown). The
combination of these four factors induced expression of INS, C-
PEPTIDE, GCG and SOMATOSTATIN (SST) proteins. In
addition, other endocrine cell markers, INS and C-PEPTIDE
proteins, were colocalized in the immunochemical assay (Figs. 3B
and C). The percentage of INS1 (C-peptide1) cells was 9.2 6 4.1% in
differentiated cell populations (Fig. 3C). Some INS1 cells expressed
GCG protein, but not SST protein (Fig. 3C). These results suggested
that the combination of Forskolin, dexamethasone, Alk5 inhibitor II
and nicotinamide induced INS1 cells from PDX11 cells.
Ability to secrete insulin by pharmacological stimulation. To
examine whether the INS1 cells induced using these four factors
secreted insulin in response to glucose stimulation, we measured
the C-peptide level in the culture medium after glucose
stimulation. There was no significant difference in C-peptide levels
by treatment with D-glucose at low (2.5 mM) or high (25 mM)
concentrations (395.2 6 95.0 pM C-PEPTIDE/mg DNA and 424.5
6 54.3 pM C-PEPTIDE/mg DNA, respectively) (Fig. 3D). On the
other hand, treatment with potassium chloride (KCl), a
depolarizing agent, and 3-isobutyl-1-methylxanthine (IBMX), a
phosphodiesterase inhibitor, resulted in a higher C-peptide level
than that obtained by D-glucose treatment at low and high
concentrations (C-peptide levels in KCl and IBMX were 1498.8 6
293.0 pM/mg DNA and 1690.3 6 397.2 pM/mg DNA, respectively)
(Fig. 3D). These results indicated that the INS1 cells induced using
these four factors could not secrete insulin in response to glucose
stimulation, but these cells had the capacity to secrete insulin in
Figure 1 | Differentiation of hPSCs into DE cells. (A) Quantitative RT-PCR analysis of definitive endoderm marker genes FOXA2 and SOX17 at day 4.
hESCswere treated with each factor for 4 days as shown in Fig. 4A. Expression levels were normalized toTBP expression. mRNA expression was relative to
that in untreated cells at day 4. Error bars indicate SD (n 5 3). (B) Upper: flow cytometric analysis of cells treated with or without three factors.
Percentage in the upper right quadrant indicates the percentage of FOXA21/SOX171 cells. Lower: percentage of FOXA21/SOX171 cells among
differentiated cells treated with each factor. Error bars indicate SD (n 5 3). Control, no factors added; Act A, 100 ng/ml activin A; CHIR, 3 mM
CHIR99021; wort, 100 nM wortmannin. Scale bar, 100 mm. (C) Expression of FOXA2 and SOX17 proteins in cells treated with three factors.
www.nature.com/scientificreports
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response to IBMX and KCl treatment. Taken together, the data
suggested that the combination of these four factors induced
premature IPCs in adhesion (2D) culture.
3D culture induces mature IPCs. We developed a differentiation
method to induce INS1 cells from hPSCs in 2D culture, but these
INS1 cells did not secrete insulin. In 2D culture, there is the
advantage that all cells are exposed to factors added to the culture
medium and immunochemical assays can be performed easily.
Furthermore, it has been reported that INS1 cells induced from
PDX11 cells in 2D culture are able to secrete insulin14,19. However,
the INS1 cells induced using our method were premature IPCs. To
acquire mature IPCs that biosynthesise and secrete insulin in
response to glucose stimulation, we improved the differentiation
method to induce mature IPCs from hPSCs (Fig. 4A). It has been
reported that 3D culture is important for the acquisition of mature
IPCs15,20,31. Cells in 2D culture were transferred to 3D culture and
treated with the combination of forskolin, dexamethasone, Alk5
inhibitor II and nicotinamide. As a result, treatment with the four
factors in 3D culture increased the expression of INS and GCG
compared with that in 3D culture without factors and 2D culture
with the four factors (Fig. 4B). The cells expressed INSULIN and C-
PEPTIDE at day 22 (Fig. 4C), but did not NKX6.1 (data not shown).
The percentage of INS1 cells was 31.4 6 2.7% in differentiated cell
populations (Fig. 4C). NKX6.1 expression was remarkably increased
at 16 day of differentiation (Fig. S4A), and MAFA expression was
increased at 22 day (Fig. 4B). In 3D culture, KhES-3-derived INS1
cells secreted insulin in response to glucose stimulation, and C-
peptide levels in response to D-glucose at low and high
concentrations were 845.4 6 351.1 pM/mg DNA and 1857.3 6
331.4 pM/mg DNA, respectively (Fig. 4D). We also found that the
percentages of INS1 cells induced from all four cell lines, including
H9, iPS(IMR90)-4 and iPS 253G1, were similar in 3D culture (Fig.
S4C). In addition, these INS1 cells secreted insulin in response to
glucose stimulation. For H9-, iPS(IMR90)-4- and iPS 253G1-derived
cells, C-peptide levels in D-glucose at low and high concentrations
Figure 2 | Differentiation of DE cells into pancreatic progenitor cells. (A) Quantitative PCR analysis of the expression of HNF6 and PDX1 at day 10.
Expression levels were normalized to TBP expression. mRNA expression was relative to that in control cells at day 10. Control cells were treated with
three factors for 4 days as shown in Fig. 4A, and then without factors for 6 days. Error bars indicate SD (n 5 3). (B) Left: cells were treated with each
factor for 6 days and then stained with an anti-PDX1 antibody at day 10. Right: percentage of PDX11 cells among differentiated cells treated with
each factor. Mean6 SD (n5 5–10). (C) Each cell line, H9, iPS (IMR90)-4 and iPS 253G1, was treated with five factors for 6 days as shown in Fig. 4A, and
stained then with an anti-PDX1 antibody at day 10. Mean 6 SD (n 5 5–10). F10, 50 ng/ml FGF10; Nog, 50 ng/ml Noggin; Dor, 1 mM dorsomorphin;
RA, 2 mM retinoic acid; FR, 3 mM FR180204. Scale bar, 100 mm.
www.nature.com/scientificreports
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were 764.0 6 27.6 pM/mg DNA and 1306.2 6 255.7 pM/mg DNA,
592.6 6 151.9 pM/mg DNA and 1056.1 6 296.3 pM/mg DNA, and
734.8 6 276.2 and 1471.2 6 202.8 pM/mg DNA, respectively
(Fig. 4D). These results suggest that our method efficiently induces
mature IPCs, and it is a robust method that can be applied to various
hPSC lines.
Discussion
We established a differentiation method that induced PDX11 cells
from hPSCs at high efficiency, suggesting that inhibition of trans-
forming growth factor (TGF)-b-induced AP-1 activation has an
important role in PDX11 cell induction. In addition, we showed that
3D culture plays an important role in the induction of functional
Figure 3 | Differentiation of pancreatic progenitor cells into INS positive cells. (A) Quantitative PCR analysis of the expression ofNKX6.1,MAFA, INS,
GCG and SST in cells treated with each factor at day 22. Expression levels were normalized to TBP expression. mRNA expression was relative to that in
control cells at day 22. Control cells were treated with each factor for 10 days as shown in Fig. 4A, and then without factors for 12 days in 2D culture. Error
bars indicate SD (n 5 3). (B) Expression of NKX6.1 and C-PEPTIDE proteins in cells treated with each factor at day 22. (C) Cells were treated with
four factors at day 22 and then stained with anti-C-PEPTIDE, -INS, -GCG and -SST antibodies. INS1 (C-PEP1) cells were 9.2 6 4.1% of total cells.
INS1/GCG1 cells were 5.2 6 4.0% of total cells. Mean 6 SD (n 5 3). (D) Secreted C-peptide in response to low (2.5 mM) or high (25 mM)
concentrations of D-glucose, 30 mM potassium chloride (KCl) or 0.5 mM IBMX was measured with a C-peptide ELISA kit at day 22. Error bars indicate
SD (n 5 3). ns; not significant. Fsk, 10 mM forskolin; Dex, 10 mM dexamethasone; Alk5i, 5 mM Alk5 inhibitor II; NA, 10 mM nicotinamide. Scale bar,
100 mm.
www.nature.com/scientificreports
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INS1 cells with insulin secretion. Approximately 30% of total cells
were mature IPCs that secreted insulin in response to glucose stimu-
lation. Furthermore, this method allows robust differentiation that
can be applied to various hPSC lines. The mature IPCs induced by
this methodmay promote the development of new therapeutic drugs
and cell therapies for diabetes.
It has been reported that activin A and Wnt3a can be used to
differentiate DE cells from hPSCs11,14,16,18,21,22,25,26. Wnt is known to
participate in at least three pathways including b-catenin, PCP and
Ca21 signalling.We found that DE cells were induced from hPSCs by
treatment with CHIR99021 instead of Wnt3a. This result suggests
that inhibition of GSK3-b is important in multiple pathways.
Furthermore, we found that the combination of activin A,
CHIR99021 and wortmannin remarkably increased the expression
of FOXA2, SOX17, HNF1B and HNF4A (Figs. 1A and S1A). Our
findings suggest that activation of nodal/activin signalling is import-
ant for differentiation into DE cells, and activation of b-catenin
signalling and inhibition of PI3Ks promote induction of DE cells.
For differentiation of DE cells into PDX11 cells, we found that
FR180204 induced PDX11 cells effectively. FR180204 is known to
selectively inhibit the kinase activity of ERK1/2 as well as TGF-b-
induced AP-1 activation31. Furthermore, inhibition of ERK activity
has been suggested to restore the activity of retinoic acid29. The
combination of FGF10, Noggin, dorsomorphin, retinoic acid and
FE180204 induced PDX11 cells at high efficiency (Fig. 2B). To evalu-
ate the effect of ERK inhibition or inhibition of TGF-b-induced AP-1
activation, we investigated the combination of FGF10, Noggin, dor-
somorphin, retinoic acid and PD0325901, a MEK inhibitor, or
SR11302, an AP-1 inhibitor. Using the combination of the four fac-
tors and PD0325901 or SR11302, the percentage of PDX11 cells was
Figure 4 | Differentiation into mature IPCs in 3D culture. (A) Scheme of differentiation into IPCs in 3D culture. (B) Quantitative PCR analysis of the
expression ofNKX6.1,MAFA, INS,GCG and SST in cells treated with each factor at day 22. Expression levels were normalized to TBP expression. mRNA
expressionwas relative to that in control cells at day 22. Control cells were treated with each factor for 10 days as shown in Fig. 4A, and thenwithout factors
for 12 days in 2D culture. Error bars indicate SD (n5 3). (C) Immunostaining of C-PEPTIDE, GCG, SST and INS proteins in cells treated with each factor
in 3D culture at day 22. INS1 cells were 31.4 6 2.7% of total cells. INS1/GCG1 cells were 6.8 6 2.4% of total cells. Mean 6 SD (n 5 5). (D) C-peptide
secreted in response to low (2.5 mM) and high (25 mM) concentrations of D-glucose was measured with a C-peptide ELISA kit at day 22 (3D culture) in
each hPSC line. Error bars indicate SD (n 5 5). Fsk, 10 mM forskolin; Dex, 10 mM dexamethasone; Alk5i, 5 mM Alk5 inhibitor II; NA, 10 mM
nicotinamide. Scale bar, 100 mm.
www.nature.com/scientificreports
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48.4 6 11.1% and 73.9 6 9.0%, respectively (Fig. S2C). Inhibition of
BMP signalling is known to mediate the activation of ERK1/2.
Therefore, the inhibition of BMP signalling suggested the import-
ance of several pathways, including Smad, and that the ERK pathway
was not important because the differentiation efficiency of PDX11
cells increased using the combination of the four factors and
FR180204 or SR11302. This result suggests that FR180204 is involved
in differentiation to PDX11 cells by inhibition of TGF-b-induced
AP-1 activation rather than inhibition of ERK. These findings indi-
cate that inhibition of BMP signalling, inhibition of TGF-b-induced
AP-1 activation and the addition of retinoic acid are important for
differentiation of DE cells into PDX11 cells.
In addition to INS, NGN3 and PAX4 can be used to monitor the
differentiation of INS1 cells from PDX11 cells, because NGN3 is an
essential transcription factor in the development of pancreatic endo-
crine tissue32–34, and PAX4, a downstream gene of NGN3, plays a
critical role in the development of b cells35. We found that the com-
bination of forskolin, dexamethasone, Alk5 inhibitor II and nicoti-
namide achieved the highest expression of NGN3, PAX4 and INS as
reported previously (Figs. 3A and S3A). Under this condition, the
percentage of INS1 cells was increased to about 10% (Fig. 3C). It has
been suggested that an increase of the cAMP level and inhibition of
TGF-b signalling play an important role in differentiation of PDX11
cells into INS1 cells. In our study, although INS1 cells were generated
at a certain efficiency, we did not observe insulin secretion by the
induced INS1 cells in response to glucose stimulation, which is con-
sistent with a previous reported22. It has been shown that mature
IPCs can be induced from NKX6.1-expressing cells20. Furthermore,
MAFA has important roles in secretion of insulin in response to
glucose stimulation in mice36. In contrast to INS expression, we
found no increase in the expression of these genes. Co-expression
of INS and GCG or SST is suggested to be a marker of premature
IPCs, because such co-expression is found at the embryonic stage of
pancreatic development in rats and humans37,38. Collectively, our
results indicated that treatment with the four factors induced pre-
mature IPCs cells in 2D culture.
To achieve further maturation of INS1 cells, we employed a 3D
culture system in the presence of the four factors. 3D culture is
thought to mimic the in vivo microenvironment39,40. Moreover,
aggregated mouse insulinoma-derived MIN6 cells, which display
characteristics of pancreatic b cells, secrete insulin in response to
glucose stimulation41. Indeed, the combination of 3D culture and
the four factors increased the expression of NKX6.1, MAFA and
INS (Figs. 4B and S4A). The percentage of INS1 cells was increased
to about 30%, but only a small proportion of INS1 cells co-expressed
GCG protein (Fig. 4C). Importantly, the INS1 cells induced by 3D
culture secreted insulin in response to glucose stimulation (Fig. 4D).
Compared with conventional 2D culture, these results indicate that
3D culture has an advantage for maturation of INS1 cells.
Furthermore, it has been reported that the differentiation efficiency
into INS1 cells varies among hPSC lines. However, our differenti-
ation method induced INS1 cells with glucose-dependent INSULIN
secretion at a similar efficiency among different hPSCs (Figs. 2C and
S4D).
In conclusion, we established a differentiation method that
allowed highly efficient differentiation of hPSCs to mature IPCs
via induction of DE cells and then PDX11 cells. In particular, we
found that treatment with FR180204 was effective for differentiation
into PDX11 cells. We also efficiently induced mature IPCs that
secreted insulin in response to glucose stimulation by treatment with
forskolin, dexamethasone, Alk5 inhibitor II and nicotinamide in 3D
culture. Moreover, our differentiation method is robust and optim-
ization for individual cell lines is unnecessary.
To date, the shortage of donor human pancreases limits applica-
tion to clinical therapy for islet transplantation. In addition, the lack
of suitable models for diabetes makes it difficult to develop new anti-
diabetic drugs. Our method might have advantages for clinical
application, because it does not use foetal bovine serum (FBS) or
mouse embryonic fibroblasts (MEFs). Moreover, our method might
be useful for development of new drugs using disease model cells
derived from disease-specific iPSCs, because it is a robust method
that induces mature IPCs at a similar efficiency from various hPSC
lines. Furthermore, the data obtained in this studymight be useful for
understanding the mechanism of insulin secretion in human pan-
creatic cells.
Methods
hPSC culture. The hESC line KhES-3 and hiPSC line 253G1 were maintained on
mitomycin-C (Wako)-treated MEF feeder cells as described previously42. The hESC
line WA09 (H9) and hiPSC line iPS (IMR90)-4 were purchased from the National
Stem Cell Bank (NSCB). These cells were maintained in accordance with the NSCB
protocols. All cells were passaged every 5 days at ratios of 153 to 157.
For pancreatic differentiation, hPSCs were passaged on Matrigel (Becton
Dickinson)-coated dishes at a density of 4.4 3 104 cells/cm2 to remove MEF feeders
using CTK. hPSCs were cultured for 4–5 days to near confluency. During induction,
the above-mentioned cells were not dissociated and treated with each factor. For DE
induction, hPSCs were washedwith PBS(1) (Sigma) and then cultured in RPMI 1640
containing 13 Glutamax I and 1% B27 without insulin (All purchased from Life
Technologies) supplemented with 100 ng/ml activin A (eBioscience), 3 mM
CHIR99021 (Stemgent) and 100 nM wortmannin (Sigma) for 2 days, and then
100 ng/ml activin A and 3 mM CHIR99021 for a further 2 days. Subsequently, the
cells were washed with PBS(1),the supplements were changed to 50 ng/ml FGF10
(R&D systems), 50 ng/ml Noggin (R&D systems), 1 mM dorsomorphin (Stemgent),
2 mM retinoic acid (Sigma) and 3 mM FR1890204 (Calbiochem), and the cells were
cultured for 3 days. Then, the cells were treated with 50 ng/ml Noggin, 1 mM dor-
somorphin, 2 mM retinoic acid and 3 mM FR1890204 in RPMI 1640 containing 13
Glutamax I and 1% B27 without insulin for 3 days. The cells were rinsed with PBS(1)
and then cultured in Dulbecco’s modified Eagle’s medium (DMEM) containing L-
glutamine (Sigma), 1% B27 without insulin, 10 mM forskolin (Sigma), 10 mM dex-
amethasone (Sigma), 5 mMAlk5 inhibitor II (Calbiochem) and 10 mMnicotinamide
(Sigma) for 12 days. At day 22, the cells were cultured in low glucose DMEM (Sigma)
containing B27 without insulin and supplemented with 10 mM forskolin, 10 mM
dexamethasone, 5 mM Alk5 inhibitor II and 10 mM nicotinamide.
3D culture. Differentiated cells cultured in the combination of FGF10, Noggin,
dorsomorphin, retinoic acid and FR180204 in adhesion culture for 10 days were
transferred and incubated in 3D culture for 12 days. To aggregate the cells,
differentiated cells in 2D culture were dissociated with 200 U/ml collagenase type IV
(Life Technologies) and then passed through a 100-mm cell strainer. The dissociated
cells were centrifuged at 330 g for 5 min at 4uC three times. The cells were then
cultured in 6-well plates with an Ultra-Low Attachment Surface (Corning) for 3 days
in DMEM with 1% B27 without insulin, 10 mM forskolin, 10 mM dexamethasone,
5 mM Alk5 inhibitor II, 10 mM nicotinamide and 10 mM Y27632 (Wako). Then,
Y27632 was omitted from the medium that was changed every 3 days for 8 days. At
day 22, aggregated cells were cultured in low glucose DMEM (Sigma) containing B27
without insulin and supplemented with 10 mM forskolin, 10 mM dexamethasone,
5 mM Alk5 inhibitor II and 10 mM nicotinamide for 1 day.
Quantitative real-time PCR. Total RNA was isolated from cells in 2D culture with
Trizol (Life Technologies) and treated with recombinant DNase I (Takara Bio). In 3D
culture, total RNA was isolated from cells using a PureLink RNA Mini Kit (Life
Technologies). Reverse transcription was performed with SuperScript III (Life
Technologies) using random hexamers according to the manufacturer’s instructions.
Primers for RT-PCR are shown in Table S2. Quantitative PCRwas carried out using a
7500 Real-Time PCR system (Life Technologies). The reaction mixture consisted of
Power SYBR Green PCRMaster Mix (Life Technologies), 0.5 nM of each primer and
cDNA. The expression levels of each gene were normalized to those of the
housekeeping gene TATA box binding protein (TBP). All quantitative PCR primers
were obtained from Sigma Genosys.
Flow cytometric analysis. Differentiated hPSCs were dissociated by treatment with
4.8 mMEDTA (Sigma) in PBS(-) (Sigma) for 2–5 min and then 0.05% trypsin/EDTA
(Life Technologies) in DMEM for 1 min. After washing with 2% FBS (Cell Culture
Bioscience) in DMEM and then 2% FBS in PBS(-), the cells were fixed with 2%
paraformaldehyde (Nacalai Tesque) for 15 min on ice. After washing with 2% FBS in
PBS(-), the cells were treated with 90%methanol (Wako) in PBS(-) for 15 min on ice.
After rinsing with 2% FBS in PBS(-), the cells were incubated for 30 min at 4uCwith a
rabbit anti-FOXA2 antibody (1550, CST) diluted in 0.1% bovine serum albumin
(BSA; Sigma)/PBS(-). Then, the cells were washed with 2% FBS in PBS(-) and
incubated for 30 min at 4uC with Alexa Fluor 488 donkey anti-rabbit IgG (151000,
Life Technologies) and an APC-conjugated goat anti-SOX17 antibody (1550, R&D
systems) diluted in 0.1% BSA/PBS(-). The cells were then rinsed twice with 2% FBS in
PBS(-). Fluorescence intensities were analysed on a FACSCalibur flow cytometer
(Becton Dickinson) with CellQuest software.
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Immunochemical assay. Cells were rinsed with DMEM or RPMI 1640 three times
and then fixed in 4% paraformaldehyde for 15 min at room temperature. The cells
were then blockedwith 5%donkey serum (Millipore) and 0.3%TritonX-100 (Nacalai
Tesque) in PBS(-) for 1 h at room temperature. Aggregated cells were rinsed DMEM
twice and fixed in 4% paraformaldehyde for 25–30 min at room temperature and
then rinsed with 0.1% Triton X-100. Cryosections (5 mm) were obtained using OCT
compound (Sakura) and a Leica CM1850 (Leica). The sections were incubated with
5% goat (Life Technologies) and 5% donkey serum and 0.1% Triton X-100 in PBS(-)
for 1 h at room temperature. The cells were then incubated overnight at 4uC with the
following primary antibodies: rabbit anti-FOXA2 (15400; CST), mouse anti-SOX17
(156000; Origene), rabbit anti-PDX1 (15100; CST), mouse anti-NKX6.1 (15300;
DSHB), mouse anti-C-PEPTIDE (15300; Sanbio), guinea pig anti-INSULIN
(152000), rabbit anti-GLUCAGON (15200; Sigma) and rabbit anti-
SOMATOSTATIN (151000; Dako). After washing with PBS(-) three times, the cells
were incubated for 1 h at room temperature with Alexa Fluor 488- or 594-conjugated
donkey or goat anti-rabbit, -mouse or -guinea pig IgG (151000; Life Technologies).
Nuclei were counterstainedwithDAPI (Sigma). To quantify the percentage of PDX11
cells, 16 images/well were acquired using an ArrayScan VTI HCS Reader (Thermo)
and analyzed with Cellomics BioApplications (Thermo). The percentage of PDX11
cells was normalized to the percentage of cells stained with the secondary antibody
only. The number of INS1/C-PEPTIDE1 cells relative to the total number of nuclei
stained with DAPI is indicated as the percentage of C-PEPTIDE1 cells (n 5 3, total
aggregated cells 5 6).
C-peptide enzyme-link immunosorbent assay (ELISA). After pre-incubation with
Krebs-Ringer solution containing bicarbonate, HEPES and D-glucose (KRBH;
129 mM NaCl, 4.8 mM KCl, 2.5 mM CaCl2, 1.2 mM KH2PO4, 1.2 mM MgSO4,
10 mMHEPES, 2.5 mMD-Glucose (all purchased fromWako) and 0.1% (w/v) BSA)
at 37uC for 2 h, the samples were incubated with KRBH containing 2.5 mM or
25 mM D-glucose or 30 mM KCl (Wako) or 0.5 mM IBMX (Sigma) at 37uC for 1 h.
The C-peptide level in culture supernatants wasmeasured with a human C-PEPTIDE
ELISA kit (Mercodia) according to manufacturer’s instructions. Cells were lysed in
Spheroid Lysis Buffer (Scivax), and dsDNA content was measured by a PicoGreen
dsDNA Quantitation Kit (Life Technologies) and Wallac 1420 multilabel/
Luminescence counter (PerkinElmer).
Statistical analysis. Data are presented as the means 6 standard deviation (SD) of
three or five independent experiments. Statistical significance was evaluated by the
Student’s t-test.
1. Shapiro, A. M. et al. Islet transplantation in seven patients with type 1 diabetes
mellitus using a glucocorticoid-free immunosuppressive regimen. The New
England journal of medicine 343, 230–238, doi:10.1056/nejm200007273430401
(2000).
2. Shapiro, A. M. et al. International trial of the Edmonton protocol for islet
transplantation. The New England journal of medicine 355, 1318–1330,
doi:10.1056/NEJMoa061267 (2006).
3. White, S. A., Shaw, J. A. & Sutherland, D. E. Pancreas transplantation. Lancet 373,
1808–1817, doi:10.1016/s0140-6736(09)60609-7 (2009).
4. Takahashi, K. et al. Induction of pluripotent stem cells from adult human
fibroblasts by defined factors. Cell 131, 861–872, doi:10.1016/j.cell.2007.11.019
(2007).
5. Yu, J. et al. Induced pluripotent stem cell lines derived from human somatic cells.
Science (New York, N.Y.) 318, 1917–1920, doi:10.1126/science.1151526 (2007).
6. Guo, T. & Hebrok, M. Stem cells to pancreatic beta-cells: new sources for diabetes
cell therapy. Endocrine reviews 30, 214–227, doi:10.1210/er.2009-0004 (2009).
7. Van Hoof, D., D’Amour, K. A. & German, M. S. Derivation of insulin-producing
cells from human embryonic stem cells. Stem cell research 3, 73–87, doi:10.1016/
j.scr.2009.08.003 (2009).
8. Park, I. H. et al. Disease-specific induced pluripotent stem cells.Cell 134, 877–886,
doi:10.1016/j.cell.2008.07.041 (2008).
9. Dimos, J. T. et al. Induced pluripotent stem cells generated from patients with ALS
can be differentiated into motor neurons. Science (New York, N.Y.) 321,
1218–1221, doi:10.1126/science.1158799 (2008).
10. Kondo, T. et al. Modeling Alzheimer’s disease with iPSCs reveals stress
phenotypes associated with intracellular Abeta and differential drug
responsiveness. Cell Stem Cell 12, 487–496, doi:10.1016/j.stem.2013.01.009
(2013).
11. Maehr, R. et al. Generation of pluripotent stem cells from patients with type 1
diabetes. Proceedings of the National Academy of Sciences of the United States of
America 106, 15768–15773, doi:10.1073/pnas.0906894106 (2009).
12. Assady, S. et al. Insulin production by human embryonic stem cells. Diabetes 50,
1691–1697 (2001).
13. Phillips, B. W. et al. Directed differentiation of human embryonic stem cells into
the pancreatic endocrine lineage. Stem cells and development 16, 561–578,
doi:10.1089/scd.2007.0029 (2007).
14. D’Amour, K. A. et al. Production of pancreatic hormone-expressing endocrine
cells from human embryonic stem cells. Nature biotechnology 24, 1392–1401,
doi:10.1038/nbt1259 (2006).
15. Jiang, J. et al. Generation of insulin-producing islet-like clusters from human
embryonic stem cells. Stem Cells 25, 1940–1953, doi:10.1634/stemcells.2006-0761
(2007).
16. Kroon, E. et al. Pancreatic endoderm derived from human embryonic stem cells
generates glucose-responsive insulin-secreting cells in vivo. Nature biotechnology
26, 443–452, doi:10.1038/nbt1393 (2008).
17. Tateishi, K. et al. Generation of insulin-secreting islet-like clusters from human
skin fibroblasts. The Journal of biological chemistry 283, 31601–31607,
doi:10.1074/jbc.M806597200 (2008).
18. Chen, S. et al. A small molecule that directs differentiation of human ESCs into the
pancreatic lineage.Nat Chem Biol. 5, 258–265, doi:10.1038/nchembio.154 (2009).
19. Zhang, D. et al. Highly efficient differentiation of human ES cells and iPS cells into
mature pancreatic insulin-producing cells. Cell Res. 19, 429–438, doi:10.1038/
cr.2009.28 (2009).
20. Kelly, O. G. et al. Cell-surface markers for the isolation of pancreatic cell types
derived from human embryonic stem cells. Nature biotechnology 29, 750–756,
doi:10.1038/nbt.1931 (2011).
21. Thatava, T. et al. Indolactam V/GLP-1-mediated differentiation of human iPS
cells into glucose-responsive insulin-secreting progeny. Gene Ther. 18, 283–293,
doi:10.1038/gt.2010.145 (2011).
22. Kunisada, Y., Tsubooka-Yamazoe, N., Shoji, M. & Hosoya, M. Small molecules
induce efficient differentiation into insulin-producing cells from human induced
pluripotent stem cells. Stem cell research 8, 274–284, doi:10.1016/j.scr.2011.10.002
(2012).
23. Sander, M. & German, M. S. The beta cell transcription factors and development
of the pancreas. Journal of molecular medicine (Berlin, Germany) 75, 327–340
(1997).
24. Habener, J. F., Kemp, D. M. & Thomas, M. K. Minireview: transcriptional
regulation in pancreatic development. Endocrinology 146, 1025–1034,
doi:10.1210/en.2004-1576 (2005).
25. Johannesson, M. et al. FGF4 and retinoic acid direct differentiation of hESCs into
PDX1-expressing foregut endoderm in a time- and concentration-dependent
manner. PLoS One 4, e4794, doi:10.1371/journal.pone.0004794 (2009).
26. Ameri, J. et al. FGF2 specifies hESC-derived definitive endoderm into foregut/
midgut cell lineages in a concentration-dependent manner. Stem Cells 28, 45–56,
doi:10.1002/stem.249 (2010).
27. Cai, J. et al. Generation of homogeneous PDX1(1) pancreatic progenitors from
human ES cell-derived endoderm cells. J Mol Cell Biol. 2, 50–60, doi:10.1093/
jmcb/mjp037 (2010).
28. Nostro, M. C. et al. Stage-specific signaling through TGFbeta family members and
WNT regulates patterning and pancreatic specification of human pluripotent
stem cells. Development 138, 861–871, doi:10.1242/dev.055236 (2011).
29. Antonyak, M. A., McNeill, C. J., Wakshlag, J. J., Boehm, J. E. & Cerione, R. A.
Activation of the Ras-ERK pathway inhibits retinoic acid-induced stimulation of
tissue transglutaminase expression in NIH3T3 cells. The Journal of biological
chemistry 278, 15859–15866, doi:10.1074/jbc.M300037200 (2003).
30. Otonkoski, T., Beattie, G.M.,Mally,M. I., Ricordi, C. &Hayek, A. Nicotinamide is
a potent inducer of endocrine differentiation in cultured human fetal pancreatic
cells. J Clin Invest 92, 1459-1466, doi:10.1172/jci116723 (1993).
31. Ohori, M. et al. Identification of a selective ERK inhibitor and structural
determination of the inhibitor-ERK2 complex. Biochem Biophys Res Commun.
336, 357–363, doi:10.1016/j.bbrc.2005.08.082 (2005).
32. Jensen, J. et al. Independent development of pancreatic alpha- and beta-cells from
neurogenin3-expressing precursors: a role for the notch pathway in repression of
premature differentiation. Diabetes 49, 163–176 (2000).
33. Gradwohl, G., Dierich, A., LeMeur,M.&Guillemot, F. neurogenin3 is required for
the development of the four endocrine cell lineages of the pancreas. Proceedings of
the National Academy of Sciences of the United States of America 97, 1607–1611
(2000).
34. Jensen, J. N., Rosenberg, L. C., Hecksher-Sorensen, J. & Serup, P. Mutant
neurogenin-3 in congenital malabsorptive diarrhea. The New England journal of
medicine 356, 1781–1782; author reply 1782, doi:10.1056/NEJMc063247 (2007).
35. Sosa-Pineda, B., Chowdhury, K., Torres, M., Oliver, G. & Gruss, P. The Pax4 gene
is essential for differentiation of insulin-producing beta cells in the mammalian
pancreas. Nature 386, 399–402, doi:10.1038/386399a0 (1997).
36. Zhang, C. et al. MafA is a key regulator of glucose-stimulated insulin secretion.
Mol Cell Biol. 25, 4969–4976, doi:10.1128/mcb.25.12.4969-4976.2005 (2005).
37. Hashimoto, T. et al. Transient coappearance of glucagon and insulin in the
progenitor cells of the rat pancreatic islets. Anatomy and embryology 178,
489–497 (1988).
38. De Krijger, R. R. et al. The midgestational human fetal pancreas contains cells
coexpressing islet hormones. Developmental biology 153, 368–375 (1992).
39. Schmeichel, K. L. & Bissell, M. J. Modeling tissue-specific signaling and organ
function in three dimensions. Journal of cell science 116, 2377–2388, doi:10.1242/
jcs.00503 (2003).
40. Grayson, W. L., Ma, T. & Bunnell, B. Human mesenchymal stem cells tissue
development in 3D PET matrices. Biotechnology progress 20, 905–912,
doi:10.1021/bp034296z (2004).
41. Chowdhury, A., Dyachok, O., Tengholm, A., Sandler, S. & Bergsten, P. Functional
differences between aggregated and dispersed insulin-producing cells.
Diabetologia doi:10.1007/s00125-013-2903-3 (2013).
www.nature.com/scientificreports
SCIENTIFIC REPORTS | 4 : 4488 | DOI: 10.1038/srep04488 8
42. Suemori, H. et al. Efficient establishment of human embryonic stem cell lines and
long-term maintenance with stable S karyotype by enzymatic bulk passage.
Biochem Biophys Res Commun. 345, 926–932, doi:10.1016/j.bbrc.2006.04.135
(2006).
Acknowledgments
This work was supported by translational research of the Ministry of Health, Labour and
Welfare of Japan.
Author contributions
H.T. and H.S. designed research. H.T. performed research. H.T., N.N. and H.S. analyzed
data. H.T., H.S. wrote the paper.
Additional information
Supplementary information accompanies this paper at http://www.nature.com/
scientificreports
Competing financial interests: The authors declare no competing financial interests.
How to cite this article: Takeuchi, H., Nakatsuji, N. & Suemori, H. Endodermal
differentiation of human pluripotent stem cells to insulin-producing cells in 3D culture. Sci.
Rep. 4, 4488; DOI:10.1038/srep04488 (2014).
This work is licensed under a Creative Commons Attribution-
NonCommercial-ShareAlike 3.0 Unported license. To view a copy of this license,
visit http://creativecommons.org/licenses/by-nc-sa/3.0
www.nature.com/scientificreports
SCIENTIFIC REPORTS | 4 : 4488 | DOI: 10.1038/srep04488 9
